AM Biotech Wins Prestigious 「National Innovation Award」, Leading the Way in Bio-Pulsed Exosome Research

AM Biotech, a pioneering force in bio-pulsed exosome research, has been honored with the 21st National Innovation Award. This is a high commendation for AM Biotech’s long-standing dedication to research and innovation in the field of bio-pulsed exosomes.

AM Biotech’s groundbreaking “Cross-generational Bio-Pulse Exosome Application Platform”, which was awarded the National Innovation Award, can significantly reduce product development time and cost. Leveraging this platform, the company successfully launched Exo Giov in 2021, a cosmetic product harnessing the power of bio-pulsed exosomes for beauty and hair care. Additionally, AM Biotech is in the advanced stages of developing exosome-based treatments for a wide range of diseases, including menopause, ophthalmic disorders, otology, periodontitis, joint diseases, and chronic kidney disease.

Bio-Pulse Activation Technology

AM Biotech’s patented bio-pulse activation technology empowers the company to develop and produce high-quality bio-pulsed exosomes. Compared to conventional exosomes, AM Biotech’s exosomes exhibit significantly enhanced efficacy, with a 202% increase in protein content and a 188% increase in miRNA content. These enhancements make them highly effective in promoting cell repair and tissue regeneration.

Cross-generational Bio-Pulse Exosome Application Platform

This innovative platform is built upon AM Biotech’s patented bio-pulse activation technology and three other core technologies:

Bio-Pulse Activation Technology: Exosomes produced using this technology exhibit several to dozens of times greater efficacy in treating diseases, enhancing beauty, and promoting hair growth compared to conventional exosomes.
High-efficiency exosome production technology: Enables storage at room temperature.
Exosome Ultra-Purification Extraction Technology: Achieves a purity level of 99.99%.
Advanced Mass Production Process: Ensures consistent product quality.